Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M, Hutson T, Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong S, Melichar B, Rolland F, Oya M, Rodriguez-Lopez K, Saito K, McKenzie J, Porta C. Grünwald V, et al. Among authors: oya m. Eur Urol Oncol. 2023 Aug;6(4):437-446. doi: 10.1016/j.euo.2023.01.010. Epub 2023 Jan 29. Eur Urol Oncol. 2023. PMID: 36720658 Free PMC article. Clinical Trial.
The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study.
Tanaka N, Kikuchi E, Shirotake S, Kanao K, Matsumoto K, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Ito Y, Kosaka T, Kodaira K, Oyama M, Miyajima A, Momma T, Nakagawa K, Ueno M, Oya M. Tanaka N, et al. Among authors: oya m. Eur Urol. 2014 Jan;65(1):227-34. doi: 10.1016/j.eururo.2012.11.050. Epub 2012 Dec 1. Eur Urol. 2014. PMID: 23219372
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.
Rini BI, Tomita Y, Melichar B, Ueda T, Grünwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E. Rini BI, et al. Among authors: oya m. Clin Genitourin Cancer. 2016 Dec;14(6):499-503. doi: 10.1016/j.clgc.2016.04.005. Epub 2016 Apr 22. Clin Genitourin Cancer. 2016. PMID: 27236772 Clinical Trial.
1,206 results